Cyclooxygenase-2 expression in non-Hodgkin's lymphomas

References

• Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. JB Lippincott, Philadelphia 1863
   Google Scholar
• Balkwll F, Mantovani A. Inflammation and cancer back to Virchow. Lancet 2001; 357: 539–545
   PubMed Web of Science ®Google Scholar
• Mann J R, Backlund M G, DuBois R N. Mechanisms of disease inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005; 2: 202–210
   PubMedGoogle Scholar
• Turini M E, DuBois R N. Cyclooxygenase-2A therapeutic target. Annu Rev Med 2002; 53: 35–57
   PubMed Web of Science ®Google Scholar
• Smith W L, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 1491–1495
   PubMed Web of Science ®Google Scholar
• Vane J R, Bakhle R M, Botting R M. Cyclooxygenase 1 and 2. Ann Rev Pharmacol 1998; 38: 97–120
   Google Scholar
• Yamamoto K, Arakawa T, Ueda S, Yamamoto S. Transcriptional roles of nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315–31320
   PubMed Web of Science ®Google Scholar
• Xie W, Herschman H R. V-src induces prostaglandin synthetase 2 gene expression by activation of the c-jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 1995; 270: 27622–27628
   PubMed Web of Science ®Google Scholar
• Inoue H, Yokosayama S, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin- endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270: 24965–24971
   PubMed Web of Science ®Google Scholar
• Matsuura H, Sakaue M, Subbaramaiah H, Kamitani H, Eling T E, Danneberg A J, et al. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem 1999; 274: 29138–29148
   PubMed Web of Science ®Google Scholar
• Huang J C, Liu D Y, Yadollahi S, Wu K K, Dawood M Y. Interleukin-1 β induces cyclooxygenase-2 gene expression in cultured endometrial stromal cells. J Clin Endocrinol Metab 1998; 83: 538–541
   PubMed Web of Science ®Google Scholar
• Tsujii M, DuBois R N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–716
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, DuBois R N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 1997; 94: 3336–3340
   PubMed Web of Science ®Google Scholar
• Sano H, Kawahito Y, Wilder R L, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785–3789
   PubMed Web of Science ®Google Scholar
• Tucker O N, Dannanberg A J, Yang E K, Zhang F, Teng L, Daly J M, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987–990
   PubMed Web of Science ®Google Scholar
• Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276–1280
   PubMed Web of Science ®Google Scholar
• Pathak S K, Sharma R A, Steward W P, Mellon J K, Griffiths T RL, Gescher A J. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer 2005; 41: 61–70
   PubMed Web of Science ®Google Scholar
• Fu Y G, Sung J JY, Wu K C, Wu H P, Yu J, Chan M, et al. Inhibition of cancer-associated angiogenesis by anti-sense Cox-2 transfectants. Cancer Lett 2005; 224: 243–252
   PubMed Web of Science ®Google Scholar
• Sano H, Kuwahito Y, Wilder R L. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1997; 55: 3785–3789
   Web of Science ®Google Scholar
• Mohammed S I, Knapp D W, Bostwick D G, Foster R S, Khan K N, Masferrer J L, et al. Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Res 1999; 59: 5647–5650
   PubMed Web of Science ®Google Scholar
• Kujubu D A, Reddy S T, Fletcher B S, Herschman H R. Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem 1993; 268: 5425–5430
   PubMed Web of Science ®Google Scholar
• Kargman S L, O'Neill G P, Vickers P J, Evans J F, Mancini J A, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556–2559
   PubMed Web of Science ®Google Scholar
• Kutchera W, Jones D A, Matsunami N, Groden J, McIntyre T M, Zimmerman G A, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci 1996; 93: 4816–4820
   PubMed Web of Science ®Google Scholar
• Wilson K T, Fu S, Ramanujam K S, Meltzer S J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929–2934
   PubMed Web of Science ®Google Scholar
• Ladetto M, Vallet S, Trojan A, Dell'Aquilla M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005; 105: 4784–4791
   PubMed Web of Science ®Google Scholar
• Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S. Cyclooxygenase-2 expression in lymphomas. Leuk Lymphoma 2004; 45: 1395–1399
   PubMed Web of Science ®Google Scholar
• Li H L, Sun B Z, Ma F C. Expression of cox-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2004; 10: 1862–1866
   PubMed Web of Science ®Google Scholar
• Konturek P C, Konturek S J, Pierzchalski P, Starzynska T, Marlicz K, Hartwich A, et al. Gastric MALT-lymphoma, gastrin and cyclooxygenases. Acta Gastroenterol Belg 2002; 65: 17–23
   PubMed Web of Science ®Google Scholar
• Taketo M M. Cyclooxygenase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998; 90: 1529–1536
   PubMed Web of Science ®Google Scholar
• Oshima M, Dinchuk J E, Kargman S L, Oshira H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase-2. Cell 1996; 87: 803–809
   PubMed Web of Science ®Google Scholar
• Taketo M M. Cox-2 and colon cancer. Inflamm Res 1998; 47(Suppl 2)S112–S116
   PubMedGoogle Scholar
• Zweifel B S, Davis T W, Ornberg R L, Masferrer J L. Direct evidence for role of cyclooxygenase-2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002; 62: 6706–6711
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, et al. Increased cyclooxygenase-2 expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000; 30: 73–81
   PubMed Web of Science ®Google Scholar
• Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2 and survival. Clin Cancer Res 2003; 9: 1741–1749
   PubMed Web of Science ®Google Scholar
• Ermert I, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase enzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003; 9: 1604–1610
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Yang S C, Baratelli F, Lin J F, Atianzar K, et al. Tumor cyclooxygenase-2 dependent suppression of dendritic cell function. Clin Cancer Res 2003; 9: 961–968
   PubMed Web of Science ®Google Scholar
• Zhang H, Sun X F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97: 1037–1041
   PubMed Web of Science ®Google Scholar
• Guo X L, Wang L E, Du S Y, Fan C L, Peng L L, Wang P W, et al. Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer. World J Gastroenterol 2003; 9: 246–249
   PubMed Web of Science ®Google Scholar
• Kern M A, Schubert D, Sahi D, Schoneweiss M M, Mol I, Haugg A M, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885–894
   PubMed Web of Science ®Google Scholar
• Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer 2004; 11: 129–133
   PubMedGoogle Scholar
• Richardson C M, Richardson D, Swinson D EB, Swain W A, Cox G, O'Byrne K J. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005; 48: 47–57
   PubMed Web of Science ®Google Scholar
• O'Kane S L, Cackwell L, Campbell A, Lind M J. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005; 41: 1645–1648
   PubMed Web of Science ®Google Scholar
• Yamashita H, Osaki M, Ardyanto T D, Osaki M, Yoshida H, Ito H. Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 2004; 14: 565–570
   PubMed Web of Science ®Google Scholar
• Yuan A, Yu C J, Shun C T, Luh K T, Kuo S H, Lee Y C, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in nonsmall cell lung cancer patients. Int J Cancer 2005; 115: 545–555
   PubMed Web of Science ®Google Scholar
• Tan K B, Putti T C. Cyclooxygenase-2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 2005; 58: 535–538
   PubMed Web of Science ®Google Scholar
• Pannone G, Bufo P, Caiaffa M F, Serpico R, Lanza A, Lo Muzio L, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2004; 17: 273–282
   PubMed Web of Science ®Google Scholar
• Kajita S, Ruebel K H, Casey M B, Nakamura N, Lloyd R V. Role of COX-2, thromboxane A (2) synthase, and prostaglandin I (2) synthase in papillary thyroid carcinoma growth. Mod Pathol 2005; 18: 221–227
   PubMed Web of Science ®Google Scholar
• Achiwa H, Yatabe Y, Hida T, Kuroishi T, Nakamura S, Ogawa M, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinoma. Clin Cancer Res 1999; 5: 1001–1005
   PubMed Web of Science ®Google Scholar
• Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002; 33: 708–714
   PubMed Web of Science ®Google Scholar
• Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 527–534
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Lauriola L, Zannoni G F, Distefano M G, Legge F, Salutari V, et al. Expression of cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Br J Cancer 2002; 87: 1145–1152
   PubMed Web of Science ®Google Scholar
• Kim H S, Youm H R, Lee J S, Min K W, Chung J H, Park C S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003; 42: 163–170
   PubMed Web of Science ®Google Scholar
• Brebander J, Park J, Metzger R, Schneider P M, Lord R V, Holscher A H, et al. Prognostic significance of cyclooxygenase-2 mRNA expression in non-small cell lung cancer. Ann Surg 2002; 235: 440–443
   PubMed Web of Science ®Google Scholar
• Yamaguchi N H, Lichtenfets A J, Demarchi L M, da Silva A P, Garippo A L, Alves V F, et al. Cox-2, MMP-9 and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. Am J Clin Pathol 2004; 121: 78–86
   PubMed Web of Science ®Google Scholar
• Potter M, Wax J S, Anderson A O, Nordan R P. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J Exp Med 1985; 161: 996–1012
   PubMed Web of Science ®Google Scholar
• Potter M, Wax J, Jones G M. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytogenesis in a hypersusceptible BALB/c congenic strain. Blood 1997; 90: 260–269
   PubMed Web of Science ®Google Scholar
• Nugent F W, Mertens W C, Graziano S, Levitan N, Collea R, Gajra A, et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 2005; 48: 267–273
   PubMed Web of Science ®Google Scholar
• Kern M A, Schöneweib M M, Sahi D, Bahlo M, Haugg A M, Kasper H U, et al. Cyclooxygenase-2 inhibitors suppress the growth of hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004; 25: 1193–1199
   PubMed Web of Science ®Google Scholar
• Diaz-Cruz E S, Shapiro C L, Bruggeimer R W. Cyclooxygenase-2 inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocr Metab 2005; 90: 2563–2570
   PubMed Web of Science ®Google Scholar
• Brown J R, DuBois R N. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840–2855
   PubMed Web of Science ®Google Scholar
• Wun T, McKnight H, Tuscano J M. Increased cyclooxygenase-2: a potential role in the pathogenesis in lymphomas. Leuk Res 2004; 28: 179–190
   PubMed Web of Science ®Google Scholar
• Beidebeck A B, Holly E A, Sturkenboom M, Coobergh J W, Stricker B H, Leufkens H G. Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 2003; 157: 510–516
   PubMed Web of Science ®Google Scholar
• Prince H M, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504–5514
   PubMed Web of Science ®Google Scholar
• Lilly M B, Drazpia L, Sheth M, Zemskova M, Bashkirova S, Morris J. Expression of cyclooxygenase inhibitors in human leukemias and hematopoietic cells. Blood 2004; 104: 4336, Abstract
   Google Scholar
• Waskewich C, Blumenthal R D, Li H, Stein R, Goldenberg D M, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase inhibitors for growth inhibition of COX-2 negative hematopoietic and epithelial cell lines. Cancer Res 2002; 622: 2029–2033
   Google Scholar
• Burton J D, Blumenthal R D, Waskewich C, Goldenberg D M. Growth inhibition of hematologic cancer cell lines by celecoxib: both Cox-2 dependent and independent effects. Blood 2000; 99: 1318, Abstract
   Google Scholar
• Zhang M, Abe Y, Matsushima T, Nishimura J, Nawata H, Muta K. Selective cyclooxygenase-2 inhibitor NS-398 induces apoptosis in myeloma cells via Bcl-2 independent pathway. Leuk Lymphoma 2005; 46: 425–433
   PubMed Web of Science ®Google Scholar